Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Robb

Showing results (661-670 of 680) with videos related to

Pageof 68
Sort By:
Plos Computational Biology|February 4, 2015
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialPaul T Edlefsen, Morgane Rolland, Tomer Hertz, et al.
NPJ Vaccines|March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccineDavid Benkeser, Youyi Fong, Holly E Janes, et al.
JCI Insight|January 31, 2020
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functionsDavid Easterhoff, Justin Pollara, Kan Luo, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Plos Pathogens|August 1, 2017
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Plos Pathogens|September 15, 2017
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Mbio|September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Nature|September 11, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Morgane Rolland, Paul T Edlefsen, Brendan B Larsen, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
Pageof 68

Showing results (661-670 of 680) with videos related to

Sort By:
Pageof 68
Plos Computational Biology|February 4, 2015
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialPaul T Edlefsen, Morgane Rolland, Tomer Hertz, et al.
NPJ Vaccines|March 10, 2023
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccineDavid Benkeser, Youyi Fong, Holly E Janes, et al.
JCI Insight|January 31, 2020
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functionsDavid Easterhoff, Justin Pollara, Kan Luo, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Plos Pathogens|August 1, 2017
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Plos Pathogens|September 15, 2017
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Mbio|September 9, 2025
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Elena E Giorgi, Danica Shao, et al.
Nature|September 11, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Morgane Rolland, Paul T Edlefsen, Brendan B Larsen, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
Pageof 68